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Background: The 22q13 deletion syndrome (Phelan–
McDermid syndrome) is characterised by a global
developmental delay, absent or delayed speech, gener-
alised hypotonia, autistic behaviour and characteristic
phenotypic features. Intranasal insulin has been shown to
improve declarative memory in healthy adult subjects and
in patients with Alzheimer disease.
Aims: To assess if intranasal insulin is also able to
improve the developmental delay in children with 22q13
deletion syndrome.
Methods: We performed exploratory clinical trials in six
children with 22q13 deletion syndrome who received
intranasal insulin over a period of 1 year. Short-term
(during the first 6 weeks) and long-term effects (after
12 months of treatment) on motor skills, cognitive
functions, or autonomous functions, speech and com-
munication, emotional state, social behaviour, behavioural
disorders, independence in daily living and education were
assessed.
Results: The children showed marked short-term
improvements in gross and fine motor activities, cognitive
functions and educational level. Positive long-term effects
were found for fine and gross motor activities, nonverbal
communication, cognitive functions and autonomy.
Possible side effects were found in one patient who
displayed changes in balance, extreme sensitivity to touch
and general loss of interest. One patient complained of
intermittent nose bleeding.
Conclusions: We conclude that long-term administration
of intranasal insulin may benefit motor development,
cognitive functions and spontaneous activity in children
with 22q13 deletion syndrome.
Besides its involvement in glucose metabolism,
insulin also acts as a neuropeptide in the central
nervous system, modulating plastic neuronal
mechanisms assumed to be involved in memory
processing. When given intranasally, insulin
reaches the cerebrospinal fluid and alters brain
functions without relevant absorption into the
bloodstream.6 Intranasal insulin administration
improves declarative memory in healthy subjects
and patients with Alzheimer disease (AD).7–12
Assuming that intranasal insulin may be able to
at least partially compensate for the cognitive
deficits caused by ProSAP/Shank3 haploinsuffi-
ciency, we performed exploratory clinical trials in
six children with 22q13 deletion syndrome.
The 22q13 deletion syndrome (Phelan–
McDermid syndrome), first described by Watt et
al in 1985,1 is characterised by a global develop-
mental delay, generalised hypotonia, inability to
reach various physical and mental milestones,
severe expressive speech delay or even loss of
verbal skills, normal or accelerated growth, and
minor physical features.2–4 Of particular interest in
this microdeletion syndrome is the general devel-
opmental impairment, in particular of cognition
and memory functions. It is assumed that these
features result from haploinsufficiency of the
ProSAP2/Shank3 gene, which triggers the produc-
tion of postsynaptic scaffolding proteins.
Consequently, the development of dendritic spines
is impaired.5
METHODS
Six children with 22q13 deletion syndrome were
enrolled in the study. Written informed consent
was obtained from each individual family. All six
patients underwent regular examinations by the
same examiner. Anthropometric data (height,
weight, head circumference) were collected and
blood levels of glucose, cortisol and insulin anti-
bodies were determined after 6 and 12 months of
treatment.
The six children received intranasal insulin
treatment for 12 months. For intranasal adminis-
tration, insulin (40 IU/ml; Actrapid, Novo Nordisk,
Mainz, Germany) was diluted with 0.9% saline
solution to a concentration of 20 IU/ml so that
each 0.1 ml puff from the nasal atomiser (Aero
Pump, Hochheim, Germany) contained a dose of
2 IU insulin. Subjects received one dose of 2 IU
insulin per day during the first 3 days according
to the standard subcutaneous insulin therapy in
children with type 1 diabetes mellitus. Dosage
was increased gradually at 3 day intervals, until
the final dosage of about 0.5–1.5 IU/kg/day
(TID) was reached. Blood glucose was measured
with a portable glucometer 30 minutes after
each administration during the initial treatment
period—that is, until the maximum treatment
dosage was reached. Baseline fasting blood
glucose levels in all patients were between 4.2
and 5.0 mmol/l.
Neurodevelopmental examinations were per-
formed before and about 1 year after treatment
started. Electroencephalography was performed
before the start of treatment. Parents were asked
to observe and record (on videotape) new skills,
changes in autonomous functions, movement,
cognitive abilities, speech development and com-
munication skills, emotional state, social contact,
behaviour and independence in daily living. After
6 weeks and 1 year of treatment, the parents were
asked to fill in a questionnaire assessing short-term
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(first 6 weeks) and long-term (12 months) treatment effects on
a scale ranging from 210 (most extreme degree of aggravation)
to + 10 (extremely positive development), with 0 indicating no
changes.13 The German version14 has been extended to include
additional specific items and a more detailed rating scale. It is an
established tool used in the daily routine to assess developmental
changes in mentally disabled children, and contains nine sections
of questions about developmental status (table 1). Ratings were
compared with clinical observations made by the examiner
and with observations of psychologists, physiotherapists and
occupational therapists made during routine examinations.
RESULTS
Patient 1
This was a boy with karyotype 46,XY, r(22).ish
r(22)(p13q13.1)(TUPLE1+, bcr+, ARSA2,Tel22q2). At time of
diagnosis, he was 2 years old. The child had marked cognitive
developmental delay, absence of expressive speech, autistic
behaviour, minor but generalised muscular hypotonia with
uncoordinated ataxic movements (walking at 15 months),
restlessness, marked sleep disturbance, persistent screaming,
mouthing and chewing, normal growth, large fleshy hands and
feet, deep-set eyes, pointed chin, dolicocephaly, and dysplastic
fingernails and toenails.
At the start of treatment, at the age of 3 years, weight was
13.7 kg (10th to 25th centile), 96.5 cm (25th to 50th centile).
MRI showed an arachnoidal cyst and large cysterna magna. He
was on levomepromazin, phenobarbital and pipamperon, and
receiving physiotherapy and occupational therapy.
After a few weeks of treatment (maximum dose of intranasal
insulin: 20 IU/day), obvious changes were found in sweating,
sleeping without interruption, emotional balance, motor func-
tions (eg, moving with improved postural control, steering a
tricycle, drawing a line with a pencil), concentration over longer
time periods (eg, looking at books, remembering animals after
visiting the zoo). The child understood more words, showed
empathy and could help when getting dressed, and also ceased
his stereotypic behaviour. After 12 months of treatment, the
improvement continued, especially in sleep rhythm, motor
skills, attention span and expression of emotions. No progress in
speech development was recorded (table 2). There were no
reported side effects.
Patient 2
This was a girl with karyotype 46,XX, del(22)(q13).ish
del(22)(q13.3q13.3)(ARSA-). She was 9 months old at the time
of diagnosis. At the age of 10 days a large ovarian cyst had been
removed. She grew too rapidly during the first 2 years of life and
had recurrent upper airway infections. At the age of 16 months,
she exhibited global developmental delay. Phenotypic features
were a flat middle face, high forehead, deep-set eyes, ptosis, a
bulbous nose, and dysplastic nails and finger pads (figs 1, 2).
At the start of treatment, aged 16 months, weight was 12 kg
(97th centile) and height 86 cm (.97th centile). MRI showed a
narrowed corpus callosum. She was on no medication and was
receiving physiotherapy.
The short-term effects of insulin (maximum dose 17.5 IU/day)
were normalisation of obstipation and body temperature, greater
agility, progress in gross and fine motor functions (eg, reaching
across the midline of the body, coordination of complex move-
ments), more perseverance in activities, longer concentration
spans. However, as a consequence of increased mobility, more
risk-taking behaviour was also noticed. Long-term effects were
found for autonomous functions (eg, stable body temperature,
fewer infections, uncomplicated eating behaviour, chewing),
gross and fine motor functions (eg, more body tension, grasping
with more precision), or cognitive performance (eg, longer
attention spans). There was progress in nonverbal communica-
tion (eg, pointing with her finger) and emotional regulation, and
the girl rarely showed stereotypic behaviour. She actively took
part in dressing and undressing and could anticipate dangerous
situations quite well (table 2). There were no reported side effects.
Patient 3
This was a girl with karyotype 46, XX, del(22)(q13.33). She was
3 years old at the time of diagnosis. Although she showed
Table 1 Behavioural questionnaire for the assessment of developmental progress13
Section Categories and items
1. Autonomous functions 1. Sweating/body temperature/digestion/defecation (eg, sweats more, sweats less, body temperature better regulated)
2. Sleeping behaviour (eg, sleeps peacefully, sleeps less/more, can stay awake longer during daytime)
3. Eating behaviour (eg, shows more appetite, eats more, can be fed longer, with less problems, can feed themselves)
2. Motor skills 4. Activity level (eg, moves more/less than before)
5. Hand movements (eg, grips, manipulates, points better than before )
6. Gross motor functions (eg, has made progress, more strength, is more stable)
3. Cognitive abilities 7. Attention span (eg, when listening, looking at books, playing)
8. Interest and motivation in new situations and activities (eg, explores more)
9. Memory functions (eg, seems to remember sequences better, understands and remembers rules of playing)
4. Speech and Communication 10. Understanding speech (eg, understands speech better, is more attentive in listening)
11. Speech and vocalisation (eg, uses new sounds, new syllables, new words)
12. Use of nonverbal/alternative ways of communication (eg, looks longer at someone, points, uses gestures in order to express needs)
5. Emotional state 13. Emotional stability (eg, agitation, self injury, crying, screaming, shouting, calms down quicker)
14. Child expresses feelings like, eg, joy, sadness, anger, interest
15. Child reacts to someone else’s feelings, cries or laughs with others
6. Social behaviour 16. Child shows interest in other children, imitates what others do, feeds the doll
7. Behaviour disorders 17. Stereotype movements (eg, repetitive movements with hands or feet, reaction to stress), preferences in playing behaviour (eg, needs
special smells or surfaces)
8. Independence in daily living 18. Changes in daily activities (eg, feeding, dressing, choosing, deciding, using the toilet)
9. Education 19. Education in activities of daily living, eg, child shows more obedient behaviour, accepts compromises more easily, tolerates changes
better
20. Child anticipates dangers/needs control
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hypotonia during the first 2 years, she could sit and walk
without assistance quite early, and was skiing and swimming at
the age of 8.5 years. Vocalisation started at the age of 2 years,
but she spoke only two-word sentences. She was restless, with a
short attention span, and showed aggressive and autistic
behaviour. She had deep-set eyes and dysplastic flat finger
nails. She was receiving physical, speech and occupational
therapy.
At the start of treatment, she was aged 8.5 years, with weight
of 28 kg (50–75th centile), height 123 cm (3–10th centile) and
head circumference 52 cm (50–75th centile). She was receiving
physical, speech and occupational therapy.
The short-term effects of insulin (maximum dose 12 IU/day)
were not positive. The patient showed less motor activity and
walked with an unstable gait. She appeared to be very
introverted and not interested in her surroundings. She did
not like to be touched and her behaviour was much more
difficult to control. Therefore, treatment was stopped after
5 weeks. However, the patient showed improvement over the
long term. Especially during the subsequent 3 months, the girl
exhibited marked progress in gross and fine motor abilities (eg,
she learned to swim) and in her cognitive abilities (eg, she could
play with her dolls over a period of 20 minutes). She showed
Table 2 Effects of intranasal insulin administration as assessed with a questionnaire on developmental progress after 6 weeks (time t1) and
12 months (time t2)13
Patient 1 2 3 4 5 6
Sex Male Female Female Female Male Female
Age* 3 years 16 months 8.5 years 9.5 years 5.5 years 26 months
Questions t1 t2 t1 t2 t1 t2 t1 t2 t1 t2 t1 t2
1 5 5 3 7 0 0 0 0 0 0 0 –
2 7 7 0 0 0 21 0 0 0 0 0 –
3 5 5 2 5 0 2 0 2 0 0 5 –
4 7 7 7 8 27 0 2 2 3 22 0 –
5 5 5 6 4 0 3 2 5 0 1 3 –
6 5 5 5 8 23 5 2 4 0 8 2 –
7 8 3 3 3 0 3 3 8 0 3 4 –
8 8 5 2 7 28 0 0 3 3 5 3 –
9 5 3 0 4 0 0 0 4 0 1 3 –
10 8 5 0–1 7 0 2 2 5 0 3 2 –
11 3 3 0 0 0 5 2 9 0 0 0 –
12 5 3 0 7 25 4 3 8 0 2 3 –
13 6 3 0 0 25 2 2 5 0 1 5 –
14 5 3 0 6 23 2 0 7 0 1 0 –
15 5 5 2 3 0 0 1 4 0 0 0 –
16 5 3 0 8 29 2 1 2 0 2 3 –
17 5 5 2 7 0 0 0 3 0 22 1 –
18 5 5 1 9 0 2 0 6 0 1 0 –
19 5 4 0 4 0 0 2 8 0 0 2 –
20 5 5 27 8 0 0 0 2 0 1 0 –
*At time treatment onset is indicated.
Note that treatment was stopped after 5 weeks in patient 3 but subsequent long-term effects were assessed; no long-term data are available for patient 6.
Figure 1 Patient 2. Characteristic facial phenotype. Figure 2 Patient 2. Dysplastic toenails.
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significant progress in verbal communication (eg, using more
words and sentences; expressing wishes by using several words,
eg, ‘‘May I go outside?’’) and social behaviour (eg, she was
interested in other children and wanted to play with them).
Education and behaviour control in everyday life were much
easier.
Patient 4
This was a girl with karyotype 46, XX, del(22)(q13.32 mos),
who was 6.5 years old at the time of diagnosis. At the age of
7 months, she was able to sit, and at the age of 15 months she
was able to walk. She could also ride a bicycle and climb trees.
At 6 years of age, she had a vocabulary of 40–50 words and
could communicate in short sentences. She later became
dyspractic and showed a marked loss of speech. At the age of
9 years, she exhibited autistic-like, self-aggressive behaviour,
pain intolerance and restlessness. She could read and calculate
with three-figure numbers. She had deep-set eyes, a rounded
nose tip and a prominent chin.
At the start of treatment, aged 9.5 years, weight was 33 kg
(75–90th centile) and height 130.8 cm (25–50th centile). She
was on lamotrigin and receiving speech therapy and facilitated
communication assistance.
The short-term effects (maximum dose 14 IU/day) resulted
in a more calm and balanced mood. The child showed better
gross and fine motor abilities (increased motor activity with
more precision in her movements, eg, in threading pearls),
prolonged attention spans (eg, she typed up to two pages with
assistance) and was more alert. She seemed to be more
competent in situations of daily living and showed less self-
aggressive behaviour, was more compliant towards educational
interventions and took part in social activities. Positive long-
term effects were seen, especially in motor skills, autonomy and
activities of daily life (eg, slicing bread, using the remote control
of the TV set, unloading the dishwasher). In general, the girl’s
attention span became longer and she showed a remarkable
progress in her playing behaviour. She showed more interest in
other children and strong positive emotional reactions to other
people (eg, with longer periods of eye contact, showing
happiness and sadness, comforting others). She began to imitate
speech and to communicate with special devices. In everyday
living she was more ready to compromise, could cope better
with frustration and showed more flexibility. There were no
reported side effects.
Patient 5
This boy had karyotype 46, XY, del (22)(q13.3). He was
20 months old at the time of diagnosis. He was sitting at
24 months and walking at 36 months. He grew too fast during
the first 3 years of life. He had muscular hypotonia and
developed hydronephrosis due to obstructive uropathy. His
speech abilities at 10 months consisted of double syllables, but
later stagnated. At the age of 5 years he showed autistic-like
behaviour, restlessness, short attention spans, self-aggressive
behaviour and no verbal communication. His phenotypic
features were a rounded nose tip, puffy eyelids, persistent
embryonal finger pads, and flat and hypoplastic fingernails.
At the start of treatment, he was aged 5.5 years with weight
of 21.2 kg (90th centile) and height of 113.5 cm (75–90th
centile). He was receiving physiotherapy.
Minor positive short-term effects of insulin (maximum dose
18 IU/day), such as increased motor activity and better general
attention were found. Positive long-term effects were seen in
gross motor coordination abilities (eg, climbing stairs without
assistance), or concentration (eg, being able to play longer). The
boy showed more interest in his surroundings (eg, in listening to
rhythms and songs). He reacted to speech and used nonverbal
communication devices. He showed jealousy and joy to see his
siblings again after being separated from them for some time
(table 2). The only reported side effect was occasional nose
bleeds.
Patient 6
This was a girl with karyotype: 46, XX, del (22)(q13.3).ish
del(22)(q13.3)(ARSA-), who was 12 months old at the time of
diagnosis. She had muscular hypotonia, was sitting at the age of
12 months, but could not walk without assistance at 2 years.
Her growth range was between the 50 and 75th centile, and she
showed normal sweating. She had obstructive uropathy on the
right side and mild aortal stenosis. At 26 months of age, she
could walk only with assistance (holding on to someone’s
hand). She showed autistic-like behaviour with restlessness and
no speech development. She did not use a pincer grip and did
not notice when objects were removed. Her phenotypic features
were a rounded nose tip, deep-set eyes and a squint, and flat and
hypoplastic fingernails.
At the start of treatment, aged aged 26 months, she weighed
10.6 kg (3–10th centile), and her height was 89 cm (50–75th
centile). She was receiving physiotherapy.
Short-term effects of insulin (maximum dose 8 IU/day) a
liking to eat; she did not protest against being fed. She showed
progress in gross and fine motor abilities (eg, she was able to
point at pictures, she began to walk and could stand up without
holding on). Her attention span was significantly increased. She
showed more interest in her social surroundings, and began to
imitate gestures and to use non-verbal communication devices.
She gained much more emotional stability and flexibility. There
were no reported side effects. Unfortunately, this was lost to
follow-up so that potential long-term effects could not be
noted.
Summary of results
The effects of insulin treatment are summarised in table 2 and
averages are depicted in fig 3. In all patients, the short-term and
long-term effects seen and documented by the parents were
comparable with the observations of the examiner and the
clinical staff. Notably, all patients whose children showed
improvements wanted to continue the treatment. No treatment
effects on blood values including glucose, haemoglobin A1c,
cortisol or insulin antibodies were found after 12 months of
therapy. All auxological data remained normal.
DISCUSSION
In this exploratory clinical trial, six children suffering with
22q13 deletion syndrome were given insulin intranasally for up
to 1 year. Observations made by the children’s parents, by the
experimenter and by routine clinical staff not involved in the
experiments (ie, observers blinded to insulin treatment) jointly
indicate a beneficial effect of intranasal insulin on the cognitive
and also motor development of the patients, suggesting that
intranasal insulin might be a valuable tool to ameliorate the
condition of patients with 22q13 deletion syndrome.
Owing to the small number of patients, their different
chromosomal abnormalities (ring chromosome, mosaicism,
large versus smaller deletions) and to the variability in age and
physical/cognitive impairment, our results can only be taken as
Original article
220 J Med Genet 2009;46:217–222. doi:10.1136/jmg.2008.062141
 group.bmj.com on July 4, 2013 - Published by jmg.bmj.comDownloaded from 
a first indication of the beneficial effects of intranasal insulin in
patients with 22q13 deletion syndrome.
The short-term effects of intranasal insulin were assessed in
all six patients, but the long-term effects of continued insulin
administration could only be assessed in four. In all six patients,
the first positive changes occurred after 1 week of treatment
(4–6 IU insulin/day), with particular improvement in rest-
lessness and prolongation of attention span. After 6 weeks,
significant progress could be seen in four of the six patients,
primarily in control and coordination of gross and fine motor
functions, attention span and control of behaviour in everyday
life. These changes were corroborated by similar observations
made by non-involved therapists. After 1 year of treatment, the
four children under observation continued to show progress,
primarily in motor functions (eg, strength, new acquired
functions), understanding of speech, use of communication
devices and prolonged attention spans, improved hand func-
tioning and more autonomy in everyday life.
Patient 3, the least impaired patient, was the only one who
showed unexpected negative changes in mood, movement and
tactile sensitiveness in the first weeks of treatment. These
changes disappeared after the premature end of treatment and
were followed by remarkable improvements during the sub-
sequent 3 months. Because patients with 22q13 deletion
syndrome often show regression of skills and subsequent regain,
it is difficult to attribute this course of events to the insulin
treatment, although it may have contributed to initially
enhance and, thus, overstrained perception. Another patient
(patient 5) only showed minor beneficial short-term effects and
less pronounced long-term effects. Apart from occasional nose
bleeding in one patient, no other side effects were reported,
particularly hypoglycaemia due to intranasal insulin.
The mechanisms behind our observations cannot be derived
from our data. The ProSAP2/Shank3 gene is preferentially
expressed in cortex, cerebellum and hippocampus. It encodes a
protein involved in the stability of the postsynaptic density
(PSD) of excitatory neurons (a highly specialised submembra-
neous network of proteins). Therefore, haploinsufficiency of the
ProSAP2/Shank3 gene as found in patients with 22q13 deletion
syndrome might impair the development of dendritic spines and
even cause degradation of synapses, resulting in the impair-
ments that are seen in cognition and in gross and fine motor
functions.5
Intranasal administration effectively delivers neuropeptides
to the central nervous system (CNS), bypassing the blood–brain
barrier and avoiding systemic side effects. Using this route of
administration, a direct effect on central nervous signalling
pathways is possible.6 15 16 Intranasal administration of insulin
has been shown to influence hippocampus-dependent declara-
tive memory function in healthy volunteers,7–10 and improves
cognition and mood in patients with AD.11 12 Insulin may be
expected to increase CNS glucose uptake, thereby improving
neuronal function, which is particularly relevant in patients
with cognitive impairments.17 Synergistically, insulin may
enhance synaptic plasticity via glutamatergic/GABAergic recep-
tors and phosphoinositol 3-kinase dependent mechanisms,
although these processes probably develop with some delay.18
It has been shown that insulin receptor substrate protein 53
(IRSp53) an insulin receptor tyrosine kinase substrate, may
improve the PSD by interacting with ProSAP/Shank and may
contribute to the morphological reorganisation of spines and
synapses after insulin receptor activation.19 Intranasal insulin
may also stimulate this process in cases of reduced availability
of ProSAP/Shank proteins by increasing the expression of the
local dendritic scaffolding protein PSD 95, thus partially
compensating for the reduced availability of ProSAP/Shank
proteins and inducing cognitive improvements. Previously,
intranasal insulin was shown to be more effective in patients
with cognitive impairments who do not carry the apolipo-
protein E (APOE) e4 allele, a genetic risk factor for AD.20 In
addition, women appear to benefit from the cognitive effects of
intranasal insulin to a greater extent than men.9 The APOE-e4
status of our patients is not known and the small sample size
prevents any conclusions on differential gender effects. It would
likewise be of interest if the reaction to intranasal insulin is
affected by deletion size, as this has been previously shown to
correlate with some features of developmental retardation.21
Clearly, future studies will have to address the question of how
these factors may influence insulin effects in children with
developmental delay.
To our knowledge, this is the first report on intranasal insulin
treatment in children, in particular in patients with 22q13
deletion syndrome. As the natural development in those
children is unknown and the exploratory nature of our
experiments prevented the inclusion of a placebo group, only
tentative conclusions can be drawn from our results. Further
and more systematic studies will be necessary to elucidate
whether the beneficial effects found in our study can also be
obtained in greater samples of patients, with a particular
emphasis possible side effects of the compound. Enhanced
dose regimens might even lead to more pronounced develop-
mental improvements. The clinically astonishing short-term
changes found in our study indicate an improving effect of
intranasal insulin treatment, suggesting that insulin given in
parallel with physical, speech and occupational therapy may
support learning processes in patients with 22q13 deletion
syndrome.
Figure 3 Effects of 6 weeks (n = 6; white bars) and 12 months (n = 4;
grey bars) of intranasal insulin administration as assessed by a
questionnaire on developmental progress.13 Sum scores (mean (SEM))
are indicated for nine sections of questions with a range from210 (most
extreme degree of aggravation) to +10 (extremely positive development),
with 0 indicating no changes.
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